Company intelligence / Profile preview

REDO Neurosystems

Ownership: Private
Development stage: Preclinical

Overview

REDO Neurosystems has developed a non-invasive, neurofeedback-based medical device software that visualizes and helps patients modulate their brain’s response to chronic musculoskeletal and joint pain. Early clinical trials have been conducted, with the final trial leading to CE certification underway as of 2021–2022[5][4].

Therapeutic areas: Rheumatology
Modalities: DeviceNon-pharmacological therapySoftware (Neurofeedback)
Industry: Digital Health Medical Devices

Drug pipeline

1 asset

RELEARN

Pre-clinical

Indications: Chronic musculoskeletal pain, Chronic knee pain, Chronic low back pain

Partnerships

Aalborg University (technology transfer, research collaboration)[2][4]

Beyond the preview

Go deeper on REDO Neurosystems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REDO Neurosystems.

Explore the full profile